Molecular Cancer Therapeutics
Journal Title
- Molecular Cancer Therapeutics
ISSN
- E 1538-8514 | P 1535-7163 | 1535-7163 | 1538-8514
Publisher
- American Association for Cancer Research
Listed on(Coverage)
| JCR | 2002-2019 |
|---|---|
| SJR | 2002-2019 |
| CiteScore | 2011-2019 |
| SCIE | 2010-2021 |
| CC | 2016-2021 |
| SCOPUS | 2017-2020 |
| MEDLINE | 2016-2021 |
| EMBASE | 2016-2020 |
Active
- Active
based on the information
- SCOPUS:2020-10
Country
- USA
Aime & Scopes
- Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the journal's main focus is on small molecule and protein drugs, other molecular entities may be considered. The following guidelines, which may be revised from time to time, describe what the Editors are looking for in submitted manuscripts: /// Data/experiments are substantive and support conclusions; all key experiments are designed and performed properly. /// Sufficient detail is provided to facilitate repetition of the experiments to verify data. /// Rigorous statistical evaluation is performed. Sufficient group size is used for animal studies. /// Appropriate replicates in cellular studies are used. /// Relevant cell lines, animal models, and assays are utilized. /// Studies must be performed according to AACR and Institutional Guidelines. /// Multiple relevant cell lines (or patient specimens) are examined/used/studied to support conclusions. /// Studies are performed using relevant concentrations of agents, conditions, schedules, and other related material. Where human data exists, the data should be used to define parameters for laboratory studies. /// Appropriate controls are employed for all experiments (especially inactive analog compounds). /// In vivo studies should go beyond establishment of biological effect and show modulation of the intended target (or cellular pathway) in vivo. Pharmacokinetic (PK)/pharmacodynamics (PD) studies are extremely useful; dose-response should be demonstrated. /// Inclusion of relevant structures of compounds mentioned or used in the work is essential and enhances the readability of the paper. Studies with uncharacterized mixture of Natural Products will not be considered. /// For novel structures previously unreported, experimental details of synthesis should be included in the main body of the paper or in Supplementary Material. /// Any references or patents cited that provide the synthesis of compounds should be specific, not general, and should be easily obtained.
Homepage
Article List
1 - 0 out of 0 results.
1